- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 31.03. | PROKIDNEY CORP. - S-4, Registration of securities, business combinations | 1 | SEC Filings | ||
| 20.03. | PROKIDNEY CORP. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| 17.03. | PROKIDNEY CORP. - 10-K, Annual Report | 2 | SEC Filings | ||
| 17.03. | PROKIDNEY CORP. - 8-K, Current Report | 2 | SEC Filings | ||
| PROKIDNEY Aktie jetzt für 0€ handeln | |||||
| 17.03. | ProKidney GAAP EPS of -$0.62 | 2 | Seeking Alpha | ||
| 17.03. | PROKIDNEY CORP. Full Year Loss Increases | - | RTTNews | ||
| 17.03. | ProKidney Reports Full Year 2024 Financial Results and Business Highlights | 118 | GlobeNewswire (Europe) | Significant progress was made in 2024, including refining the Phase 3 program to accelerate rilparencel's path to market in the U.S., the release of positive Phase 2 data, restarting manufacturing... ► Artikel lesen | |
| 21.01. | PROKIDNEY CORP. - 8-K, Current Report | 1 | SEC Filings | ||
| 22.11.24 | PROKIDNEY CORP. - 8-K, Current Report | - | SEC Filings | ||
| 12.11.24 | ProKidney GAAP EPS of -$0.14 | 2 | Seeking Alpha | ||
| 12.11.24 | ProKidney Reports Third Quarter 2024 Financial Results along with Regulatory and Clinical Development Updates Following Successful FDA Type B Meeting | 132 | GlobeNewswire (Europe) | FDA confirmed in a recent FDA Type B meeting under RMAT designation that the PROACT 1 Phase 3 study could be sufficient to support a full U.S. regulatory approval of rilparencelFDA also confirmed... ► Artikel lesen | |
| 09.08.24 | ProKidney Reports Business Updates and Second Quarter 2024 Financial Results | 263 | GlobeNewswire (Europe) | Reported interim REGEN-007 data that demonstrate rilparencel's potential to preserve kidney function in patients with diabetes and advanced CKDRestarted manufacturing and resumed PROACT 1 and PROACT... ► Artikel lesen | |
| 10.06.24 | ProKidney Announces Positive Interim REGEN-007 Phase 2 Trial Data and Provides Clinical and Operational Updates | 179 | GlobeNewswire (Europe) | Interim results of REGEN-007 Phase 2 trial show stabilization of kidney function for 18 monthsSafety profile consistent with prior studies and comparable to kidney biopsyResumed manufacturing and... ► Artikel lesen | |
| 10.05.24 | ProKidney Reports Business Updates and First Quarter 2024 Financial Results | 333 | GlobeNewswire (Europe) | Final results from RMCL-002 Phase 2 trial to be presented in the Late Breaking Clinical Trials session at the European Renal Association (ERA) Congress on May 25, 2024. An investor call to provide... ► Artikel lesen |
14 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ORGANOVO | 1,930 | -100,00 % | Organovo, Inc.: Organovo Provides Update on Cash and Nasdaq Continued Listing Requirements | SAN DIEGO, April 02, 2025 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq: ONVO) ("Organovo" or the "Company"), a clinical stage biotechnology company focused on developing novel treatment approaches... ► Artikel lesen | |
| INOVIO PHARMACEUTICALS | 1,510 | -1,95 % | INOVIO Pharmaceuticals, Inc.: INOVIO Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Highlights | Significant progress toward submitting a biologics license application (BLA) for INO-3107 as a potential treatment for recurrent respiratory papillomatosis (RRP)... ► Artikel lesen | |
| GENMAB | 174,40 | +0,29 % | Genmab A/S: Genmab Announces Net Sales of DARZALEX (daratumumab) for First Quarter of 2025 | Company Announcement Net sales of DARZALEX® in the first quarter of 2025 totaled USD 3,237 millionGenmab receives royalties on worldwide net sales from Johnson & Johnson (J&J, legal entity Janssen... ► Artikel lesen | |
| LEAP THERAPEUTICS | 0,312 | -1,89 % | Leap Therapeutics, Inc.: Leap Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results | Leap to host a conference call to present updated CRC clinical data today, March 26, 2025, at 8:00 a.m. ET
CAMBRIDGE, Mass., March 26, 2025 /PRNewswire/ --... ► Artikel lesen | |
| ENVERIC BIOSCIENCES | 1,073 | -100,00 % | Enveric Biosciences, Inc. - 8-K, Current Report | ||
| VERRICA PHARMACEUTICALS | 0,404 | -5,38 % | Verrica Pharmaceuticals Inc.: Verrica Pharmaceuticals Appoints Noah L. Rosenberg, M.D., as Chief Medical Officer | WEST CHESTER, Pa., March 26, 2025 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. ("Verrica" or the "Company") (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases... ► Artikel lesen | |
| REPARE THERAPEUTICS | 1,210 | +0,83 % | Cathie Wood's ARK ETF focuses on GitLab stock, sheds Repare Therapeutics | ||
| BIOATLA | 0,324 | 0,00 % | BioAtla, Inc.: BioAtla Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Progress | CAB-EpCAM x CAB-CD3 (BA3182) Phase 1 dose-escalation study continues with data readout expected mid-2025; Dose expansion data readout anticipated 1H 2026 Mecbotamab vedotin (CAB-AXL-ADC) Q2W dosing... ► Artikel lesen | |
| RELMADA THERAPEUTICS | 0,254 | -0,78 % | Relmada Therapeutics To Present NDV-01 Data at AUA2025 | ||
| THERANEXUS | 0,371 | -0,27 % | THERANEXUS PUBLISHES ITS CASH POSITION AS OF 31 DECEMBER 2024 AND PRESENTS ITS PROGRESS REPORT | Lyon, France - 30 January 2025, 6pm CET - Theranexus, a biopharmaceutical company innovating in the treatment of rare neurological diseases, today announces publication of its cash position as... ► Artikel lesen | |
| BOUNDLESS BIO | 1,430 | +0,70 % | Boundless Bio, Inc.: Boundless Bio Appoints Robert Doebele, M.D., Ph.D., as Chief Medical Officer | SAN DIEGO, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies... ► Artikel lesen | |
| TRANSCODE THERAPEUTICS | 0,265 | -2,72 % | Transcode Therapeutics, Inc. - 10-K, Annual Report | ||
| PEPGEN | 1,340 | +0,75 % | PepGen Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights | BOSTON--(BUSINESS WIRE)--PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment... ► Artikel lesen | |
| QIAGEN | 35,980 | -1,91 % | Qiagen NV-Aktie gewinnt 1,38 Prozent (35,71 €) | An der Börse notiert die Aktie von Qiagen NV aktuell etwas fester. Das Papier kostete zuletzt 35,71 Euro. Ein Kursplus von 1,38 Prozent steht gegenwärtig für die Qiagen NV-Aktie zu Buche. Das Wertpapier... ► Artikel lesen | |
| NUVALENT | 71,64 | 0,00 % | Nuvalent, Inc. - 8-K, Current Report |
PROKIDNEY CORP gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 0,786 Euro und damit -0,57 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu PROKIDNEY CORP finden Sie auf Wallstreet Online.
